|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
Methyl
aminolevulinate
Methyl-5-aminolevulinate hydrochloride cream is
a topical
cream formulation containing the hydrochloride salt of
methyl-5-aminolevulinate, a lipophilic methyl ester of 5-aminolevulinic
acid, with photosensitizer prodrug activity. Upon topical
administration, methyl-5-aminolevulinate in the cream is selectively
absorbed by tumor cells where it is converted to the photosensitizer
protoporphyrin IX (PpIX). Upon photoirradiation, PpIX is activated and
transfers energy to oxygen, generating singlet oxygen and superoxide and
hydroxyl radicals, which may result in free-radical-mediated DNA damage
and cell death. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus).
Current developer:
PhotoCure
|
MedKoo Code#: 205533
|
|
Name: Methyl
aminolevulinate
|
|
CAS#: 33320-16-0
Synonym: Methyl
aminolevulinate. brand name: Metvix.
IUPAC/Chemical name:
methyl 5-amino-4-oxo-pentanoate
|
|
Chemical structure
|
Theoretical analysis
|
|

|
MedKoo Code#: 205533
Name: Methyl aminolevulinate
CAS#: 33320-16-0
Chemical Formula: C6H11NO3
Exact Mass: 145.07389
Molecular Weight: 145.15644
Elemental Analysis: C, 49.65; H, 7.64; N,
9.65; O, 33.07
|
|
Availability and price:
This agent is
not in stock, may be available through custom synthesis.
To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Information about this agent
|
Methyl aminolevulinate (MAL) is a prodrug that is
metabolised to Protoporphyrin IX (sensitizer) used in photodynamic
therapy. It is marketed as Metvix. Metvix cream is applied topically and
some time later the skin is illuminated with a proprietary red light
(630 nm) source (medical lamp 'Aktilite') to activate the
photosensitiser. Metvix is developed by Photocure and Galderma has
bought all rights to Metvix. Methyl aminolevulinate was approved in New
Zealand for treatment of basal cell carcinoma, It is now approved in
many countries and has been used to treat non-melanoma skin cancer
(including basal cell carcinoma). It has some advantages over Levulan
(source:
http://en.wikipedia.org/wiki/Methyl_aminolevulinate). .
1: Devirgiliis V, Panasiti V, Fioriti D, Anzivino E,
Bellizzi A, Cimillo M, Curzio M, Melis L, Roberti V, Gobbi S, Liteo P,
Richetta AG, Calvieri S, Chiarini F, Nicosia R, Pietropaolo V.
Antibacterial activity of methyl aminolevulinate photodynamic therapy in
the treatment of a cutaneous ulcer. Int J Immunopathol Pharmacol. 2011
Jul-Sep;24(3):793-5. PubMed PMID: 21978711.
2: Haedersdal M, Katsnelson J, Sakamoto FH, Farinelli WA, Doukas AG, Tam
J, Anderson RR. Enhanced uptake and photoactivation of topical methyl
aminolevulinate after fractional CO2 laser pretreatment. Lasers Surg
Med. 2011 Sep;43(8):804-13. doi: 10.1002/lsm.21096. PubMed PMID:
21956628.
3: Fai D, Romano I, Cassano N, Vena GA. Methyl-aminolevulinate
photodynamic therapy for the treatment of erythroplasia of Queyrat in 23
patients. J Dermatolog Treat. 2011 Sep 4. [Epub ahead of print] PubMed
PMID: 21888568.
4: Antonia Pastor-Nieto M, Olivares M, Sánchez-Herreros C, Belmar P, De
Eusebio E. Occupational allergic contact dermatitis from methyl
aminolevulinate. Dermatitis. 2011 Aug 1;22(4):216-9. PubMed PMID:
21781638.
5: Pauwels C, Mazereeuw-Hautier J, Basset-Seguin N, Livideanu C, Viraben
R, Paul C, Meyer N. Topical methyl aminolevulinate photodynamic therapy
for management of basal cell carcinomas in patients with basal cell
nevus syndrome improves patient's satisfaction and reduces the need for
surgical procedures. J Eur Acad Dermatol Venereol. 2011 Jul;25(7):861-4.
doi: 10.1111/j.1468-3083.2010.03854.x. Epub 2010 Oct 3. PubMed PMID:
21668511.
6: Kitagawa KH, Bogner P, Zeitouni NC. Photodynamic therapy with methyl-aminolevulinate
for the treatment of double extramammary Paget's disease. Dermatol Surg.
2011 Jul;37(7):1043-6. doi: 10.1111/j.1524-4725.2011.02039.x. Epub 2011
Jun 1. PubMed PMID: 21631634.
7: Tierney E, Petersen J, Hanke CW. Photodynamic diagnosis of tumor
margins using methyl aminolevulinate before Mohs micrographic surgery. J
Am Acad Dermatol. 2011 May;64(5):911-8. PubMed PMID: 21496702.
8: Lee JW, Lee HI, Kim MN, Kim BJ, Chun YJ, Kim D. Topical photodynamic
therapy with methyl aminolevulinate may be an alternative therapeutic
option for the recalcitrant Malassezia folliculitis. Int J Dermatol.
2011 Apr;50(4):488-90. doi: 10.1111/j.1365-4632.2009.04377.x. PubMed
PMID: 21413966.
9: Tyrrell J, Campbell SM, Curnow A. Monitoring the accumulation and
dissipation of the photosensitizer protoporphyrin IX during standard
dermatological methyl-aminolevulinate photodynamic therapy utilizing
non-invasive fluorescence imaging and quantification. Photodiagnosis
Photodyn Ther. 2011 Mar;8(1):30-8. Epub 2010 Dec 17. PubMed PMID:
21333932.
10: Ballester I, Belinchón I, Guijarro J, Oltra F, Toledo F, Cuesta L.
Photodynamic therapy of vulvar intraepithelial neoplasia using methyl
aminolevulinate. J Dermatolog Treat. 2011 Jan 22. [Epub ahead of print]
PubMed PMID: 21254852.
11: Palm MD, Goldman MP. Safety and efficacy comparison of blue versus
red light sources for photodynamic therapy using methyl aminolevulinate
in photodamaged skin. J Drugs Dermatol. 2011 Jan;10(1):53-60. PubMed
PMID: 21197524.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|